BCTXZ
BriaCell Therapeutics Corp. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.54
52W High
$0.70
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on pioneering immunotherapy solutions for cancer treatment, with a particular emphasis on breast cancer. Its leading candidate, Bria-IMT, has shown encouraging efficacy in early clinical trials, underscoring the company’s commitment to tackling significant unmet needs in oncology. Backed by a strong R&D framework and an experienced leadership team, BriaCell is well-positioned to drive transformative advancements in cancer therapeutics, aiming to enhance patient outcomes amidst a rapidly changing healthcare environment.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-31.92M |
| Operating Margin | 0.00% |
| Return on Equity | -175.30% |
| Return on Assets | -90.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.32 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $7.86M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
104.11%
HV 20-Day
74.21%
HV 30-Day
60.72%
HV 60-Day
87.72%
HV Rank
—
Volatility is currently expanding
Data last updated: 7/9/2026